3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
8
Terminated
7
Recruiting
7
Unknown
4
Not yet recruiting
3
Suspended
2
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
5
Thoracic
4
Head & Neck
4
Genitourinary
4
Other solid neoplasm
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Conditions
Urogenital Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Interventions
Oxaliplatin
95
Fluorouracil
84
Capecitabine
75
Gemcitabine
72
Leucovorin
68
Nivolumab
67
Bevacizumab
63
pembrolizumab
60
Magnetic Resonance Spectroscopy
52
Specimen Handling
50
Irinotecan
50
durvalumab
46
Radiotherapy
42
atezolizumab
40
Cisplatin
39
Paclitaxel
37
Biopsy
37
130-nm albumin-bound paclitaxel
34
Cetuximab
30
Carboplatin
27
Albumin-Bound Paclitaxel
26
Taxes
24
Drug Therapy
20
dehydroftorafur
19
Radiation
19
Ipilimumab
19
tislelizumab
18
Surgical Procedures, Operative
17
Standard of Care
17
Docetaxel
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Interleukin-2
×
Gastrointestinal
×
Clear all
NCT05902520
2026-01-08
ACT
AgonOx, Inc.
Phase 1
Active not recruiting
18 enrolled